Brenig Therapeutics to Showcase BT-267 Phase 1 Findings at AAN 2026 Brenig Therapeutics is set to present Phase 1 data on BT-267, a promising treatment for neurodegenerative diseases, at the AAN 2026 Annual Meeting.

Brenig Therapeutics to Showcase BT-267 Phase 1 Findings at AAN 2026 #USA #Brenig_Therapeutics #BT-267 #Chicago,_Illinois #AAN_2026

New Insights on Quality of Life Impacts for Epilepsy Patients at AAN 2026 UCB presents new data at AAN 2026 highlighting the quality-of-life challenges for epilepsy patients and their caregivers, emphasizing the need for better treatment strategies.

New Insights on Quality of Life Impacts for Epilepsy Patients at AAN 2026 #United_States #Atlanta #UCB #Epilepsy #AAN_2026